PCN171 Real World Data in Oncology: Third- and Fourth-Line Treatments Administered in Metastatic Colon-Rectal Cancer (MCRC)  by Heiman, F. et al.
A644  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
between March and April 2014 and retrieved from an extra boost of ONCOVIEW 
database. ONCOVIEW is a continuous syndicated study on cancer treatment in 
the hospital setting, based on the collection of patient questionnaires. Patients 
inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual 
therapy line and no participation in a phase II or III clinical study. Information col-
lected included patient demographic characteristics, mCRC characteristics (TNM 
Classification, Karnofsky performance status scale and mutation analyses) and 
treatments (actual and previous schedules, dosages and durations). Furthermore, 
an evaluation of the “Rechallenge” occurrence, in other words the use in 3rd or 
later line of treatment of drugs previously used, has been performed. Results: 
261 patients diaries have been collected: 218 out of 261 patients were in third 
line of treatment, while 43 patients were in 4th or later treatment line. The 
most administered schema among third line patients was Capecitabine alone 
(63 patients), while the most used schema in fourth line was a combination of 
Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered 
in 3rd line and 67% of molecules administered in 4th line were used in previ-
ous lines. ConClusions: Results from the present study underline the unmet 
medical need in 3rd or later line of treatment of mCRC patients and the need for 
additional evidence-based treatment options.
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objeCtives: Minimizing waste of the use of drugs allows optimization of available 
resources in a scarce environment. Grouping patients may be an alternative to 
reduce drug waste in oncology. The aim of this study is to evaluate the economic 
impact of streamlined form of dispensation and percentage of drug wastage of 
the total drug expenditure in supplementary health system. Methods: Patients 
receiving antineoplasic treatment for stomach, colon, rectosigmoid, rectum, lung 
and breast cancer were eligible and selected retrospectively from the private mar-
ket administrative claims database (Evidencias database). Name and any other 
personal identification were not available at the database. Prescription and date 
of administration were collected from 3 selected private institutions consider-
ing large to small size in terms of patients. Waste of drug was calculated and it 
was defined as unavoidable or inappropriate clearance of partially drug use. All 
analyses were performed according to regimen and disease. Saving costs were 
calculated assuming minimization of waste by optimizing fully drug among group 
patients. Costs were derived from Simpro table. Exchange rate used was 1.00USD 
= 2.20BRL. Results: Seventeen drugs were identified among reported chemo-
therapy regimens in which 11 were analyzed due to potential of saving costs. From 
these, only 6 drugs could be rationalized. The optimization of drug dispensing 
would lead to a year savings of US$ 83.587,88, US$ 17.592,22 and US$ 8.225,24 to 
a large, medium and small clinic, respectively. Calculated drug wastage repre-
sented from 2% to 8% of the total drug expenditure, regarding on the antineoplastic 
used. Five of the 11 drugs did not cause savings due to small number of patients 
receiving those treatments. ConClusions: Grouping patients for drug wastage 
minimization is an effective way to reduce costs. Furthermore, savings can be 
increased by gathering patients of different diseases.
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objeCtives: Lung cancer is the leading cause of death among cancer patients; 
therefore, the detection of a pulmonary nodule cannot be ignored. With the 
increasing prevalence of lung nodule detection, the investigation requires a large 
number of health care resources. The objective of this study was to measure the 
health care resources used for the investigation of pulmonary nodules. Methods: 
A retrospective medical chart review was conducted at the CHUM-Hotel-Dieu in 
Montreal, Canada. Eligible patients were selected consecutively using the elec-
tronic appointment book of the pulmonary clinic, from January 1st 2011 to May 
23rd 2012. Inclusion criteria were: 40 year-old and over, presenting a pulmonary 
nodule ranging from 0.8 to 3.0 cm with no prior history of cancer in the last 
5 years and no history of lung cancer. Patient’s demographics, nodule charac-
teristics, medical information and resources utilization were extracted for 
each eligible patient. Results: A total of 47 patients (23 women and 24 men, 
mean age = 64) were included in the analysis. The mean nodule size was 1.8 
cm. Thirteen patients (28%) had a benign nodule and 34 (72%) had a malignant 
nodule. The most frequent non-invasive procedures were Thorax CT-Scan, PET-
Scan and Chest X-ray performed at least once in respectively 96%, 85% and 77% 
of patients. The minimally invasive procedures (bronchoscopy and transthoracic 
needle biopsy) and the invasive procedures (thoracoscopy and thoracotomy) 
were mostly performed in patients who were eventually diagnosed with a lung 
cancer. On average, patients with a benign nodule underwent 0.77 minimally 
invasive or invasive procedures vs. 1.94 for patients with a malignant nodule 
(p= 0.028). ConClusions: A significant amount of health care resources are 
deployed for the investigation of pulmonary nodules. This study tends to demon-
strate that minimally invasive and invasive procedures are mostly deployed for 
the diagnosis of malignant nodules.
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outcomes following BRCA testing in women with ovarian cancer and their female 
first-degree relatives. Two strategies are being compared: no testing versus BRCA 
testing. Estimates of cancer incidence and mortality, uptake and impact of risk-
reducing surgery and costs of BRCA testing, cancer treatment and palliative care 
were based on literature review. Outcomes are expressed as quality-adjusted life 
years (QALYs). One-way sensitivity analyses are conducted for key model param-
eters. Results: We first evaluated the cost-effectiveness of gene testing in relatives 
of ovarian cancer patients with BRCA mutations. Results showed this was associ-
ated with an ICER below the UK cost-effectiveness threshold of £20,000 per QALY 
gained compared with no testing. Sensitivity analyses showed the results were 
robust. ConClusions: We demonstrate that gene testing in unaffected female 
first-degree relatives of women with ovarian cancer due to BRCA mutations is cost 
effective. The final results will consider the cost effectiveness of offering BRCA 
testing to all eligible ovarian cancer cases and their unaffected female first-degree 
relatives.
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objeCtives: Existing evidence suggests that around 49% of patients with bone 
metastases from solid tumors show evidence of renal impairment (eGFR< 60ml/
min/1.73m2) following diagnosis of bone metastases with approximately 80% of 
them developing chronic kidney disease. The objective of this analysis is to assess 
the economic and clinical burden of renal impairment in prostate cancer patients 
with bone metastases. Methods: Patients with a diagnosis of prostate cancer and 
bone metastases from the Adelphi Real World Disease Specific Programme USA 
2012 were included in the analyses. Propensity Score Matching was used; patients 
with evidence of renal impairment were matched with those without on a 1:1 basis, 
controlling for: age, BMI, smoking status, employment status, and relevant comor-
bidities. Outcomes included number of hospitalizations and length of stay in the 
past 12 months prior to the point of data collection. A Wilcoxon sign-rank test 
was used to quantify the impact of renal impairment. Results: 109 patients per 
group were included in the analyses (total 218). The renal impairment group was 
estimated to have an increased risk of inpatient visits of 63% (p= 0.036) compared 
to the control group (0.78 vs 0.48 inpatient visits per patient per year). Additionally, 
the renal impairment group had a mean of 2.43 (p= 0.027) more inpatient days per 
year than the control group (5.00 vs 2.56 inpatient days per patient per year). It was 
also observed that the patients in the renal impairment group were less likely to 
have received chemotherapy (37% vs 47% received chemotherapy). ConClusions: 
Findings suggest an increase in health care utilization in the hospital setting in 
prostate cancer patients with bone metastases and renal impairment. In addition, 
compromised renal function in those patients may potentially have restricted the 
use of nephrotoxic chemotherapy agents.
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objeCtives: To estimate the expected benefits from a pivotal randomised con-
trolled trial of predictive biomarkers for high dose alkylating chemotherapy (HDAC) 
in triple negative breast cancer (TNBC) and to inform decisions about the design 
and priority of further studies. Methods: A markov decision model compared 
treating 40- years old TNBC women with HDAC based on four predictive biomarker 
strategies: 1) BRCA1-like by MLPA testing; 2) BRCA1-like by aCGH testing, 3) strategy 
1 followed by XIST and 53BP1 testing; and 4) strategy 2 followed by XIST and 53BP1 
testing, versus treating all patients with standard chemotherapy. A Dutch societal 
perspective and a 20-year time horizon were used. Input data came from literature 
and expert opinions. We assessed four primary outcomes: the expected value of 
(partial) perfect information (EV(P) PI), the expected value of sample information 
(EVSI) and the expected net benefit of sampling (ENBS) for the ongoing pivotal 
TNM trial (NCT01057069) and/or potential future studies. Results: The population 
EVPI was € 663 million (M). The EVPPI suggests prioritizing further research towards 
effectiveness parameters, specifically prevalence and positive predictive value of 
the biomarkers; response rates in biomarker negative patients and TNBC unclas-
sified patients, which are estimated to collectively have a value of information of 
circa € 630M. The value of further research on transition probabilities is estimated 
at € 41M, followed by utilities at € 34M and costs at € 34M. Further information on 
transition probabilities could be gathered from the TNM trial and that of effec-
tiveness parameters and costs from accompanying studies to this trial, altogether 
estimated to have an ENBS of € 657 M. ConClusions: Further research on predic-
tive biomarkers for HDAC should focus on gathering transition probability data 
from the current TNM trial, and on accompanying studies to derive data on other 
effectiveness parameters and costs.
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objeCtives: The objective of this study was to assess the oncologists’ real clini-
cal practice in the management of mCRC patients, with a focus on the 3rd, 4th 
and later lines of therapy in Italy. Methods: Data presented in this study were 
collected from medical records obtained by Italian oncologists on mCRC patients 
